A Phase Ib/II, Multicenter Study to Evaluate the Efficacy and Safety of DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma

NCT07059650 Phase 1/Phase 2 RECRUITING

This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.

Details

Lead sponsor	Dizal Pharmaceuticals
Phase	Phase 1/Phase 2
Status	RECRUITING
Enrolment	150
Start date	2025-08-19
Completion	2030-10

Conditions

• Diffuse Large B-Cell Lymphoma

Interventions

• DZD8586+R-CHOP
• DZD8586+R-GemOx
• DZD8586+BR

Primary outcomes

• Part A: Incidence and severity of adverse events — Approximately 5 years
• Part B: Objective response rate (ORR) — Approximately 5 years

Countries

China